qnrA1、qnrB1 和 qnrS1 基因对 gyrA 和 parC 突变的同源大肠埃希菌分离株中氟喹诺酮活性的体外影响。
In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
机构信息
Department of Microbiology, University of Seville, Seville, Spain.
出版信息
Antimicrob Agents Chemother. 2011 Mar;55(3):1266-9. doi: 10.1128/AAC.00927-10. Epub 2010 Dec 20.
Abstract
This article provides an analysis of the in vitro effect of qnrA1, qnrB1, and qnrS1 genes, combined with quinolone-resistant Ser83Leu substitutions in GyrA and/or Ser80Arg in ParC, on fluoroquinolone (FQ) resistance in isogenic Escherichia coli strains. The association of Ser83Leu substitution in GyrA, Ser80Arg substitution in ParC, and qnr gene expression increased the MIC of ciprofloxacin to 2 μg/ml. qnr genes present in E. coli that harbored a Ser83Leu substitution in GyrA increased mutant prevention concentration (MPC) values to 8 to 32 μg/ml. qnr gene expression in E. coli may play an important role in selecting for one-step FQ-resistant mutants.
摘要
本文分析了 qnrA1、qnrB1 和 qnrS1 基因与 GyrA 中的 Ser83Leu 取代和/或 ParC 中的 Ser80Arg 取代相结合对同源大肠埃希菌菌株中氟喹诺酮（FQ）耐药性的体外影响。GyrA 中的 Ser83Leu 取代、ParC 中的 Ser80Arg 取代和 qnr 基因表达的联合作用使环丙沙星的 MIC 增加至 2 μg/ml。在携带 GyrA 中 Ser83Leu 取代的大肠埃希菌中存在的 qnr 基因将突变预防浓度（MPC）值提高至 8 至 32 μg/ml。大肠埃希菌中 qnr 基因的表达可能在选择一步 FQ 耐药突变体方面发挥重要作用。
相似文献
1
In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.qnrA1、qnrB1 和 qnrS1 基因对 gyrA 和 parC 突变的同源大肠埃希菌分离株中氟喹诺酮活性的体外影响。
Antimicrob Agents Chemother. 2011 Mar;55(3):1266-9. doi: 10.1128/AAC.00927-10. Epub 2010 Dec 20.
2
Fluoroquinolone resistance and molecular characterization of gyrA and parC quinolone resistance-determining regions in Escherichia coli isolated from poultry.氟喹诺酮耐药性及鸡源大肠杆菌中 gyrA 和 parC 喹诺酮耐药决定区的分子特征。
Poult Sci. 2014 Apr;93(4):856-63. doi: 10.3382/ps.2013-03627.
3
Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.新突变的出现及其在拓扑异构酶 IV 基因中的积累赋予了大肠杆菌分离株对氟喹诺酮类药物的高度耐药性。
Int J Antimicrob Agents. 2010 Jan;35(1):76-9. doi: 10.1016/j.ijantimicag.2009.08.003. Epub 2009 Sep 24.
4
Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.在大肠埃希菌尿路感染中，gyrA 和/或 parC 突变还是外排泵表达与氟喹诺酮类耐药的关系更密切？一项统计学分析研究。
Int J Antimicrob Agents. 2012 Dec;40(6):516-20. doi: 10.1016/j.ijantimicag.2012.07.019. Epub 2012 Oct 13.
5
Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu.qnrA1、qnrB1 和 qnrS1 对携带有或不带有 GyrA 突变 Ser83Leu 的大肠杆菌引起的实验性肺炎模型中环丙沙星和左氧氟沙星疗效的影响。
J Antimicrob Chemother. 2013 Jul;68(7):1609-15. doi: 10.1093/jac/dkt063. Epub 2013 Mar 14.
6
Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.携带质粒介导喹诺酮类耐药决定因子的临床肺炎克雷伯菌和大肠埃希菌分离株的表型和基因型特征多样化。
Microb Drug Resist. 2011 Sep;17(3):363-7. doi: 10.1089/mdr.2011.0034. Epub 2011 May 12.
7
[Mutations of gyrA gene and parC gene in fluoroquinolone-resistant Escherichia coli isolates from sporadic diarrheal cases].[散发性腹泻病例中氟喹诺酮耐药大肠埃希菌分离株的gyrA基因和parC基因变异]
Kansenshogaku Zasshi. 2006 Sep;80(5):507-12. doi: 10.11150/kansenshogakuzasshi1970.80.507.
8
Discrepancies in fluoroquinolone clinical categories between the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI for Escherichia coli harbouring qnr genes and mutations in gyrA and parC.欧洲抗菌药物敏感性试验委员会（EUCAST）与美国临床和实验室标准协会（CLSI）在携带qnr基因以及gyrA和parC基因突变的大肠杆菌氟喹诺酮临床分类上存在差异。
J Antimicrob Chemother. 2011 Jun;66(6):1405-7. doi: 10.1093/jac/dkr117. Epub 2011 Mar 21.
9
Occurrence of fluoroquinolones and fluoroquinolone-resistance genes in the aquatic environment.氟喹诺酮类药物和氟喹诺酮类耐药基因在水环境中的出现。
Sci Total Environ. 2013 Feb 1;444:508-14. doi: 10.1016/j.scitotenv.2012.11.077. Epub 2013 Jan 3.
10
Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.从鸡中分离的大肠杆菌的氟喹诺酮耐药性及gyrA和parC基因突变
J Microbiol. 2005 Oct;43(5):391-7.
引用本文的文献
1
Genomic Characterization of Isangi: A Global Perspective of a Rare Serovar.伊桑吉的基因组特征：一种罕见血清型的全球视角
Antibiotics (Basel). 2023 Aug 11;12(8):1309. doi: 10.3390/antibiotics12081309.
2
QUIRMIA-A Phenotype-Based Algorithm for the Inference of Quinolone Resistance Mechanisms in .QUIRMIA——一种基于表型的推断喹诺酮耐药机制的算法
Antibiotics (Basel). 2023 Jun 28;12(7):1119. doi: 10.3390/antibiotics12071119.
3
Aquatic Environments as Hotspots of Transferable Low-Level Quinolone Resistance and Their Potential Contribution to High-Level Quinolone Resistance.水生环境作为可转移低水平喹诺酮耐药性的热点及其对高水平喹诺酮耐药性的潜在贡献
Antibiotics (Basel). 2022 Oct 27;11(11):1487. doi: 10.3390/antibiotics11111487.
4
Controlling Antimicrobial Activity of Quinolones Using Visible/NIR Light-Activated BODIPY Photocages.利用可见光/近红外光激活的硼二吡咯光笼控制喹诺酮类药物的抗菌活性
Pharmaceutics. 2022 May 17;14(5):1070. doi: 10.3390/pharmaceutics14051070.
5
Interplay between IncF plasmids and topoisomerase mutations conferring quinolone resistance in the Escherichia coli ST131 clone: stability and resistance evolution.IncF质粒与赋予大肠杆菌ST131克隆喹诺酮耐药性的拓扑异构酶突变之间的相互作用：稳定性和耐药性演变
Eur J Clin Microbiol Infect Dis. 2021 Nov 17. doi: 10.1007/s10096-021-04358-4.
6
Acquisition of the Gene Lowers the Target Mutation to Impede the Evolution of a High-Level Colistin-Resistant Mutant in .该基因的获得降低了目标突变，从而阻碍了[具体对象]中高水平耐黏菌素突变体的进化。
Infect Drug Resist. 2021 Aug 10;14:3041-3051. doi: 10.2147/IDR.S324303. eCollection 2021.
7
The pentapeptide-repeat protein, MfpA, interacts with mycobacterial DNA gyrase as a DNA T-segment mimic.五肽重复蛋白 MfpA 作为 DNA T 段类似物与分枝杆菌 DNA 拓扑异构酶相互作用。
Proc Natl Acad Sci U S A. 2021 Mar 16;118(11). doi: 10.1073/pnas.2016705118.
8
CTX-M-33, a CTX-M-15 derivative conferring reduced susceptibility to carbapenems.CTX-M-33，一种对碳青霉烯类药物敏感性降低的CTX-M-15衍生物。
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01515-19. Epub 2019 Sep 16.
9
Low-Level Antimicrobials in the Medicinal Leech Select for Resistant Pathogens That Spread to Patients.低水平抗菌药物在医用水蛭中选择耐药病原体，并传播给患者。
mBio. 2018 Jul 24;9(4):e01328-18. doi: 10.1128/mBio.01328-18.
10
Characterization of the complete sequences and stability of plasmids carrying the genes aac(6')-Ib-cr or qnrS in Shigella flexneri in the Hangzhou area of China.分析中国杭州地区携带 aac(6')-Ib-cr 或 qnrS 基因的质粒的全序列特征及其稳定性。
World J Microbiol Biotechnol. 2018 May 18;34(6):72. doi: 10.1007/s11274-018-2454-3.
本文引用的文献
1
In vivo selection of aac(6')-Ib-cr and mutations in the gyrA gene in a clinical qnrS1-positive Salmonella enterica serovar Typhimurium DT104B strain recovered after fluoroquinolone treatment.氟喹诺酮类药物治疗后临床分离的 qnrS1 阳性鼠伤寒沙门氏菌 DT104B 株中 aac(6')-Ib-cr 的体内选择和 gyrA 基因突变。
J Antimicrob Chemother. 2010 Sep;65(9):1945-9. doi: 10.1093/jac/dkq262. Epub 2010 Jul 16.
2
Plasmid-mediated quinolone resistance: a multifaceted threat.质粒介导的喹诺酮耐药性：一种多方面的威胁。
Clin Microbiol Rev. 2009 Oct;22(4):664-89. doi: 10.1128/CMR.00016-09.
3
Interplay in the selection of fluoroquinolone resistance and bacterial fitness.氟喹诺酮耐药性选择与细菌适应性之间的相互作用。
PLoS Pathog. 2009 Aug;5(8):e1000541. doi: 10.1371/journal.ppat.1000541. Epub 2009 Aug 7.
4
Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection.在大肠杆菌尿路感染的小鼠模型中，由qnrA1和qnrS1基因或gyrA突变导致的对氟喹诺酮类药物的低水平耐药性对环丙沙星杀菌活性的影响。
Antimicrob Agents Chemother. 2009 Oct;53(10):4292-7. doi: 10.1128/AAC.01664-08. Epub 2009 Jul 27.
5
Plasmid-mediated quinolone resistance.质粒介导的喹诺酮耐药性
Expert Rev Anti Infect Ther. 2008 Oct;6(5):685-711. doi: 10.1586/14787210.6.5.685.
6
Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.环丙沙星和左氧氟沙星在由缺乏孔蛋白、表达活性外排并产生QnrA1的肺炎克雷伯菌引起的实验性肺炎中的活性。
Clin Microbiol Infect. 2008 Jul;14(7):691-7. doi: 10.1111/j.1469-0691.2008.02020.x.
7
A unified anti-mutant dosing strategy.一种统一的抗突变给药策略。
J Antimicrob Chemother. 2008 Sep;62(3):434-6. doi: 10.1093/jac/dkn229. Epub 2008 Jun 10.
8
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.拓扑异构酶突变的联合效应在大肠杆菌对氟喹诺酮耐药性中的作用
Antimicrob Agents Chemother. 2007 Nov;51(11):4205-8. doi: 10.1128/AAC.00647-07. Epub 2007 Aug 6.
9
Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.表达质粒携带喹诺酮耐药决定子qnrA1的肠杆菌科细菌对氟喹诺酮类药物的突变预防浓度
Antimicrob Agents Chemother. 2007 Jun;51(6):2236-9. doi: 10.1128/AAC.01444-06. Epub 2007 Apr 2.
10
Mutant selection window hypothesis updated.突变选择窗假说更新。
Clin Infect Dis. 2007 Mar 1;44(5):681-8. doi: 10.1086/511642. Epub 2007 Jan 24.
Zotero 插件